Department of Medicine, University College of Medical Sciences, Delhi, India.
Department of Endocrinology, University College of Medical Sciences, Delhi, India.
Am J Trop Med Hyg. 2024 Feb 13;110(3):512-517. doi: 10.4269/ajtmh.22-0695. Print 2024 Mar 6.
Although the short-term mortality of patients with COVID-19 infection and hyperglycemia has been well documented, there is little available data regarding longer-term prognosis. The presence of diabetes has not only influenced disease severity but has also impacted its transmission dynamics. In this study, we followed a historical cohort of patients without previous history of diabetes who presented with moderate to severe COVID-19 and were found to have hyperglycemia (random blood glucose > 140 mg/dL) at the time of admission. We evaluated the need for antidiabetic therapy in these patients at the end of 6 months and the risk factors associated with persistent hyperglycemia determined by monthly values of self-monitored blood glucose. Of the seventy participants who were followed telephonically, 54 (77%) continued to receive antidiabetic therapy or have persistent hyperglycemia (> 140 mg/dL) at the end of 6 months. Persistent hyperglycemia at the end of follow-up, was found to be associated with a higher blood glucose at presentation.
虽然 COVID-19 感染和高血糖患者的短期死亡率已有充分记录，但关于其长期预后的数据却很少。糖尿病的存在不仅影响疾病的严重程度，也影响其传播动态。在这项研究中，我们对一组无既往糖尿病史的患者进行了随访，这些患者患有中度至重度 COVID-19，且在入院时随机血糖>140mg/dL。我们评估了这些患者在 6 个月时是否需要进行抗糖尿病治疗，并根据每月自我监测血糖值确定与持续高血糖相关的危险因素。在通过电话随访的 70 名参与者中，54 名（77%）在 6 个月结束时继续接受抗糖尿病治疗或持续存在高血糖（>140mg/dL）。在随访结束时发现持续高血糖与入院时更高的血糖水平有关。
